Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 5Esophageal Neoplasms 5Pancreatic Neoplasms 4Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Liver Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Pathologic Complete Response 1Pancreatic Ductal Adenocarcinoma 1Disease 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 3Pancreaticoduodenectomy 2Oxaliplatin 2Irinotecan 2titanium silicide 1tislelizumab 1sonidegib 1paricalcitol 1mitazalimab 1lenvatinib 1ivosidenib 1irinotecan sucrosofate 1glucoraphanin 1devimistat 1Transurethral Resection of Prostate 1Tissue Banks 1Taxes 1Specimen Handling 1Saline Solution 1S 1 (combination) 1Ropivacaine 1Robotic Surgical Procedures 1Radiomics 1Positron Emission Tomography Computed Tomography 1Parturition 1PEGPH20 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Losartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Ductal Adenocarcinoma × Positron Emission Tomography Computed Tomography × Gastrointestinal × Clear all
NCT03851237 2026-05-08

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

Washington University School of Medicine

Phase 1 Completed
69 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡